Home > Keywords > Thématique > Science

Science

Articles

  • Meet Vect-Horus at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit, Boston, August 21-23, 2024
    21 August 2024, by Emmanuelle BETTENDORF

    VECT-HORUS S.A.S. will be presenting a poster at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit!
    This high-profile event is taking place in Boston, MA from August 20-22, and Pavlo Shpak-Kraievskyi, Project leader, is looking forward to attending.
    Poster Title: VECTrans® Technology for CNS Targeting by Lipid Nanoparticles
    📆 Save the date: 3:30pm ET, Wednesday August 21st
    🌐 Learn More: https://ter.li/b5vw3f

  • New PCT patent application covering anti Transferrin receptor vectors
    13 October 2020, by Elodie DORMES

    Vect-Horus has filed a PCT patent application covering a library of vectors that target the Transferrin receptor (TfR). This patent strengthens the intellectual property of the Company with a portfolio containing now 6 patent families. This confirms its position as a major player in Blood-Brain Barrier drug delivery technology.

  • How blood–brain barrier technology is unleashing CNS therapies
    19 September, by Emmanuelle BETTENDORF

    Nature Research has republished an in-depth article on Vect-Horus in the September issue of Biopharma Dealmakers. The issue focuses on CNS related technologies and therapeutics.
    It’s well worth having a read, or re-read, of this piece, which outlines our VECTrans platform and its potential to transform the treatment of neurodegenerative disorders.
    It also touches on the science and data behind our approach and our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, (…)

  • Our latest research article is now available on bioRxiv and medRxiv
    11 July, by Emmanuelle BETTENDORF

    In this study, we explored the identification and optimization of cross-species reactive VHHs (single-domain antibodies from camelids) targeting the transferrin receptor 1 (TfR1) — a promising strategy for delivering therapeutics across the blood-brain barrier.
    We focused on two candidates, C5 and B8, which bind TfR1 in rodents, non-human primates, and humans. These VHHs show potential as molecular shuttles for transporting imaging or therapeutic agents across species — paving the way for (…)

  • Meet Vect-Horus at OTS, Barcelona, October 22-25, 2023
    12 October 2023, by Emmanuelle BETTENDORF

    Vect-Horus team will attend the 19th Annual Meeting of the Oligonucleotide Therapeutics Society from October 22nd to 25th, 2023, in Barcelona.
    We are pleased to announce that Guillaume Jacquot, Program Director, Brain & Tissue Targeting of Oligonucleotides, will give a talk entitled “TfR-targeted functional delivery of oligonucleotides to CNS tissues by local and systemic administration” on Tuesday, 24th and Emmanuelle Bettendorf, Senior Business Developer, will also be there and (…)

  • Vect-Horus demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos
    28 January 2019, by Jonathan NOWAK

    Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.
    Marion David, Pascaline Lécorché, Maxime Masse, Aude Faucon, Karima Abouzid, Nicolas Gaudin, Karine Varini, Fanny Gassiot, Géraldine Ferracci, Guillaume Jacquot, Patrick Vlieghe, Michel Khrestchatisky
    http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191052 (…)

  • Vect-Horus will join the ARVO Annual Meeting
    17 April 2024, by Emmanuelle BETTENDORF

    We’re excited to present a poster on our targeted drug delivery technology at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, taking place in Seattle, WA, USA from May 5-9, 2024.
    The poster is titled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”.
    It will be available at ARVO on May 7, 2024, from 3:30pm to 5:15pm PDT Posterboard Number 3992 - B0036 and Session (…)

  • Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member
    14 November 2024, by Emmanuelle BETTENDORF

    We’re pleased to welcome Jean-Christophe Dantonel as a new member of the Vect-Horus Board of Directors!
    Dr. Dantonel brings over two decades of profound expertise in biological sciences, project management, and clinical research to his new role.
    “He brings key skills to our company at an important stage of its development, with a combination of clinical research and business experience which will be invaluable as we innovate to develop vectors that facilitate targeting and delivery of (…)

  • Vect-Horus appoints Dr Jamal Temsamani as Director of Drug Development & Corporate
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS announced today the appointment of Dr. Jamal Temsamani as Director in charge of Drug Development & Corporate. He will lead the Company’s drug development programs from discovery to early clinical and will be in charge of industrial partnerships. Dr. Jamal Temsamani is also a member of the Management Committee of VECT-HORUS.

  • Vect-Horus announces the expansion of its Scientific Advisory Board
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS is a French biotechnology company that designs and develops peptide-vectors to facilitate the delivery of drugs or imaging agents into the brain and other organs, and in particular in tumours. VECT-HORUS announces the expansion of its Scientific Advisory Board (SAB). Chaired by Prof. Jean-Michel SCHERRMANN, this Scientific Council is composed of several personalities and opinion leaders of international renown. (…)